INTRODUCTION
The HIV-1 epidemic continues to devastate subSaharan Africa where over 25 million people are already living with HIV-1 and 1.6 million new infections occurred in 2014 [1, 2] . Prevention strategies that include antiretroviral agents have the greatest potential for reducing HIV-1 incidence. In 2012, a fixed dosed combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC; marketed as Truvada) became the first drug to be approved by the US Food and Drug Administration for preexposure prophylaxis (PrEP). The approval was based on data from Phase III HIV prevention trials that showed a 44-75% reduction in HIV acquisition in seronegative individuals using daily, oral TDF/ FTC [3, 4] . Concurrently, the WHO strongly recommended TDF with FTC or lamivudine (3TC) and a nonnucleoside reverse transcriptase inhibitor as the preferred regimen for first-line antiretroviral therapy (ART) [5] , creating concern that the same drugs used for treatment and prevention would increase the spread of drug resistance [6] . Breakthrough infection and subsequent selection of resistance with continued use of TDF/FTC PrEP during acute infection could compromise the effectiveness of first-line ART containing TDF/FTC. Conversely, the efficacy of TDF/FTC for PrEP could be reduced if the transmitted variant is from a partner failing a TDF/FTC-based ART regimen. Here, we review the current knowledge about resistance selection with the use of TDF/FTC for HIV prevention and treatment, focusing on resistance analyses from RESISTANCE TO EMTRICITABINE OR  TENOFOVIR DISOPROXIL FUMARATE IS  RARELY SELECTED IN SEROCONVERTERS  FROM TENOFOVIR DISOPROXIL  FUMARATE/EMTRICITABINE  PREEXPOSURE PROPHYLAXIS TRIALS To date, five placebo-controlled, Phase III trials were done to assess the effectiveness of daily oral TDF/ FTC PrEP in preventing HIV infection in various populations, including MSM and transgendered women in Iniciativa Profilaxis Pre-Exposició n [Preexposure Prophylaxis Initiative] (iPrEX) [7] , at-risk men and women in TDF2 [8] , discordant couples in Partners PrEP [9] , and women of reproductive age in FEM-PrEP (the Preexposure Prophylaxis Trial for HIV Prevention among African Women trial) [10] and Vaginal and Oral Interventions to Control the Epidemic (VOICE) [11 & ]. All studies included an active arm in which participants were assigned a oncedaily regimen of oral TDF/FTC, and all participants underwent monthly rapid testing for HIV seroconversion.
FTC and TDF resistance selection is infrequent in seroconverters in active product arms from TDF/FTC PrEP trials
Only five cases of resistance with M184I/V or K65R were identified by standard genotype analysis in a
KEY POINTS
Resistance to tenofovir (TNV) and emtricitabine (FTC) is infrequent (3%) from use of oral TDF/FTC for preexposure prophylaxis (PrEP) if HIV-1 infection is not present at the time PrEP is started (five cases in 160 seroconverters assigned to TDF/FTC in five PrEP trials).
Resistance to TNV and FTC is much more common (41%) if TDF/FTC PrEP is started during undiagnosed acute HIV-1 infection (seven cases in 17 participants); Acute HIV-1 infections should be excluded before starting PrEP.
Mathematical modeling shows that the number of HIV-1 infections that would be averted by PrEP greatly exceeds the number of drug-resistant infections that could occur.
The risk of HIV-1 resistance to TNV or FTC is far greater when used, it is used for antiretroviral therapy than for PrEP. combined total of 160 seroconverters assigned daily oral TDF/FTC in the five trials listed above and again in Table 1 [7-10,11 & ] . Four of these cases were in FEM-PrEP, but only one of the four is likely to have had M184V selection from PrEP failure despite adherence to TDF/FTC (intracellular TNV-DP concentrations were equivalent to taking four or more tablets per week). Two of the three other cases of M184I and V were detected within 4 and 8 weeks of study enrollment (one with detectable TNV-DP and one without, respectively) for whom acute infection at enrollment could not be ruled out, and the fourth case occurred in a participant who seroconverted 48 weeks after discontinuing TDF/FTC, thus, FTC resistance was likely transmitted from the participant's partner. In all cases, the resistance mutation became undetectable after stopping study product -M184I by 4 weeks and M184 V by 24-36 weeks [10, 12 && ], reflecting the negative effect of the 184 mutations on viral replication fitness. The fifth case of resistance occurred in VOICE: one of 61 participants who became infected on the TDF/FTC arm developed FTC resistance with a mixed population of M184 M/V. This participant had been on oral TDF/FTC 309 days from enrollment (68 days since last negative plasma collection) and had detectable plasma TNV-TP within 6 weeks of her first quarterly plasma sample collection [11 & ,13 ]. More sensitive testing for resistance using allelespecific PCR or next-generation sequencing identified an additional 10 cases of M184I or V in active arms from the five TDF/FTC PrEP trials. Low-frequency M184I variants were identified in one participant from FEM-PrEP (0.66%), two from iPrEX (0.75 and 0.53%), and two from VOICE (5.2 and 0.7%), although only one of the participants from iPrEx had detectable intracellular PMBC levels of FTC-TP [ . In VOICE, one seroconverter from the 1% tenofovir gel arm had 1.2% K65R detected by allele-specific PCR [15] . Resistance results from FACTS 001 have not yet been reported [20] .
Resistance from oral TDF PrEP has also been rarely detected. In the Bangkok tenofovir study, no cases of K65R or K70E were found in 17 seroconverters in the TDF arm, and in Partners PrEP, only one of 30 seroconverters on TDF and one of eight participants who enrolled with unrecognized acute infection had low frequency K65R or K70E [16 && ,21] . In VOICE, no instances of K65R or K70E were detected in the 58 seroconverters on the TDF arm [11 & ,13,15] . In the United States, oral TDF is a recommended alternative to TDF/FTC PrEP, although the relative efficacy of the two is unknown. Selection of K65R in clinical trials has occurred rarely with TDF and TDF/FTC PrEP. Resistance was more frequent with TDF/FTC PrEP due to selection of M184I/V, which is known to increase HIV susceptibility to TNV and reduce risk of selecting K65R [22, 23] , but studies to test this hypothesis are needed. There is also insufficient data to assess comparative risk of resistance with TDF versus TDF/FTC PrEP; therefore, the decision to use TDF over TDF/FTC must be made with individual clinical considerations.
TRANSMISSION OF RESISTANT STRAINS IN BREAKTHROUGH INFECTION WITH TENOFOVIR DISOPROXIL FUMARATE/ EMTRICITABINE PREEXPOSURE PROPHYLAXIS: ANIMAL MODELS
The low-dose repeat challenge Simian/Human Immunodeficiency Virus (SHIV) pigtail macaque model has been a valuable tool to study PrEP scenarios that cannot be addressed in human trials. Resistance could not be assessed in two macaque studies evaluating the impact of depot-medroxyprogesterone (DMPA) on the efficacy of TDF/FTC PrEP because the 24-h preinfection and 2-h postinfection dosing regimen conferred 100% efficacy [24 & ,25] . Breakthrough infection did occur in a macaque study of intermittent TDF/FTC PrEP, but resistance to TDF or FTC was not selected [26] . In macaques given a weekly dose of TDF/FTC 3 days before exposure and 2 h after challenge with a K65R-containing SHIV to simulate transmitted resistance, infection was significantly delayed compared with untreated controls, but four of six macaques did get infected [27] . By contrast, the same dosing regimen protected five of five animals from M184V-containing SHIV. This may be due to M184 V having increased susceptibility to tenofovir or reduced transmission fitness compared with wild-type virus [28] .
MATHEMATICAL MODELS PREDICT THAT PREEXPOSURE PROPHYLAXIS IS NOT A MAJOR CONTRIBUTOR TO DRUG RESISTANCE
Mathematical models have been used to study PrEP efficacy and the spread of HIV drug resistance in scenarios in which the same antiretrovirals, for example, TDF/FTC, are used for both PrEP and ART [29, 30] . Modeling predicts that PrEP used in conjunction with ART but not overlapping with ART would reduce HIV prevalence to a greater extent than ART alone, but also modestly increase drug resistance. However, several models agree that the relative contribution of ART to resistance far exceeds that from PrEP, with PrEP contributing less than 5% to the total burden of resistance [29-31,32 & ]. The most important factors contributing to drug resistance from PrEP are the frequency of breakthrough HIV infection while taking PrEP and the frequency of inadvertent PrEP use among individuals who are already infected with HIV. The persistence of transmitted resistance and duration of PrEP use by seroconverters are also major contributors to drug resistance prevalence [33] [34] [35] .
TRANSMITTED RESISTANCE AND RESISTANCE IN INDIVIDUALS FAILING TENOFOVIR DISOPROXIL FUMARATE/ EMTRICITABINE CONTAINING FIRST-LINE ANTIRETROVIRAL THERAPY
Patients failing ART are the largest contributors to prevalent drug-resistant virus. PharmAccess African Studies to Evaluate Resistance conducted a multicountry 13-site cohort study and found that although 70% of patients on first-line ART achieved HIV RNA suppression, 71% of ART failures had drug resistance. In patients on tenofovir-based regimens, almost 30% failed with K65R and half with M184 V [36] . In South African patients failing first-line ART with TDF/FTC, K65R was detected in five of 40 (12%) and M184 V/I in 12 of 40 (28%) [37] . Another South African study looking at 80 patients failing on TDFbased ART with at least one resistance mutation found 10 (12.5%) had K70E, 43 As in the macaque models described above, drug-resistant HIV with K65R originating from individuals on failing TDF/FTC-containing ART could compromise the efficacy of TDF/FTC PrEP. Fortunately, the majority of transmitted nucleoside reverse transcriptase inhibitor (NRTI) resistance in Sub-Saharan Africa is due to M184 V, whereas rates of transmitted K65R are still low. In a large meta-analysis evaluating 298 sequences from treatment-naive individuals in sub-Saharan Africa, only six (2%) had K65R, whereas 54 (18%) had M184 V [39] . The WHO threshold surveillance classification for most regions in sub-Saharan Africa for NRTI resistance still remained low (<5%) except in KwaZulu-Natal, South Africa, where NRTI resistance has been reported as both low and moderate (5-15%) [40, 41] . In a cross-sectional study of women screening for a prevention trials but ineligible to participate because of preexisting HIV infection, only one of 400 (<1%) had K65R, and four of 400 (1%) had M184 V [42] . These observations suggest that the risk of PrEP breakthrough infection with TDF-resistant HIV containing K65R is low but continued surveillance is warranted.
WHAT CAN WE DO TO MINIMIZE RESISTANCE FROM PREEXPOSURE PROPHYLAXIS?
As demonstrated by both clinical and mathematical modeling studies, the greatest risk of resistance from PrEP occurs when PrEP is used during unrecognized acute HIV infection. A point-of-care rapid antibody or nucleic acid detection test that reduces undiagnosed acute infection is critically needed both to avoid prescribing TDF/FTC PrEP to users who are already HIV infected, and to monitor PrEP users to minimize the time on PrEP after seroconverting [43 & ].
Reducing the overall prevalence of drug-resistant HIV will reduce the risk of PrEP breakthrough infection with resistant virus. PrEP is likely to be highly effective against wild-type strains, but may have reduced efficacy against strains resistant to the PrEP agent being used. T-cell counts to decline. Lack of HIV RNA monitoring of individuals on ART can lead to the accumulation of drug resistance mutations as a result of prolonged time on the failing therapy [48] . In addition, point of care tests for ARV levels or common drug resistance mutations are urgently needed so that nonadherence can be differentiated from drug resistance as the cause of treatment failure and managed appropriately [49] . Improved detection of treatment failure can prolong the lifespan of first-line therapy, limit the spread of drug-resistant HIV and preserve second-line therapy for those who have confirmed resistance to first line.
CONCLUSION
Recent data from clinical trials have shown that the potential for TDF/FTC PrEP to prevent HIV infection far exceeds the risk of resistance that could occur with its use. Resistance has been rare in PrEP trials because when drug pressure from PrEP is high, infection is unlikely to occur, but when drug pressure is low or absent, such as from nonadherence to PrEP, the risk of resistance selection is also low. Careful monitoring of resistance from TDF/FTC PrEP is required but fear of resistance is unwarranted and should not impede its implementation to prevent HIV infection. Resistance from treatment failure of TDF/FTC-containing ART will generate far more resistance than that from TDF/FTC PrEP (Fig. 1) . The challenge of preserving the efficacy of TDF/ FTC PrEP by preventing the spread of drug-resistant HIV can be met by improving individual and epidemiological monitoring for ART failure and drug resistance, simplifying ART to single tablet regimens for first, second, and third-line therapy [50 & ], maintaining a drug strong supply chain [47 & ], improving HIV diagnostics to reduce unrecognized acute HIV infection, and gaining a better understanding of cross-resistance between ART and PrEP through analysis of patient-derived viruses. Major individual and public health benefits from both PrEP and ART can be realized and sustained if appropriate actions are taken to limit the spread of HIV drug resistance.
